Michelle Y. Martin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Michelle Y. Martin has a total of 172 co-authors. Here are the top co-authors by number of shared publications:
- Robert A. Oster
Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA
11 shared publications Maria Pisu
School of Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama
10 shared publications- Maria Pisu
University of Alabama at Birmingham
10 shared publications - Gregory A. Vidal
Clinical Research and Breast Oncology Program, Lee S Schwartzberg Research Center, West Cancer Center and Research Institute, Memphis, Tennessee
9 shared publications - Ilana Graetz
Department of Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta, GA, USA
9 shared publications - Lee Steven Schwartzberg
Department of Internal Medicine, Renown Institute for Cancer and University of Nevada, Reno , Reno, NV
9 shared publications
Latest Publications
- Open Access
- 10 July 2026
- Published by Springer Nature in Journal of Cancer Education
- p. 1-11
Development of a Community-engaged Research Training Workshop for Clinician-Scientists and Early-stage Investigators
Community-engaged research (CEnR), a collaboration between academics and community partners, is an effective approach in addressing the social drivers of health (SDOH) and health disparities in local communities. Yet, CEnR training is often not a standard component of training programs in research or clinical programs. To meet the need for CEnR training, we developed and implemented a workshop to increase CEnR knowledge and skills among clinician-scientists and early-stage investigators (ESIs), and create opportunities for ongoing mentorship and professional development. In this manuscript, we discuss the organization of this workshop, learning objectives, supporting activities, and follow-up methods to facilitate a successful and engaging training experience. The workshop was developed through collaborative efforts with experts in CEnR, Community-Based Participatory Research (CBPR), cancer disparities, and SDOH. The workshop focused on (1) an introduction to CEnR and the opportunity for attendees to develop their own CEnR research ideas; (2) varied presentations, interactive activities, experiential learning, and discussion topics to fulfill the workshop’s learning objectives; (3) year-long opportunities for professional development and continued mentorship; and (4) evaluations of the workshop. Twenty-four ESIs and 11 clinician-scientists participated in the workshop. Using survey methods and descriptive statistics, the workshop was evaluated positively by participants. This manuscript provides guidance for both in-person and virtual workshop formats, from inception to implementation, and recommendations for other workshop facilitators. The impact of these workshops has the potential to have positive downstream implications for community-engaged research.
- 10 July 2026
- Published by Springer Nature in Journal of Cancer Education
- p. 1-11
Open AccessDevelopment of a Community-engaged Research Training Workshop for Clinician-Scientists and Early-stage Investigators
Community-engaged research (CEnR), a collaboration between academics and community partners, is an effective approach in addressing the social drivers of health (SDOH) and health disparities in local communities. Yet, CEnR training is often not a standard component of training programs in research or clinical programs. To meet the need for CEnR training, we developed and implemented a workshop to increase CEnR knowledge and skills among clinician-scientists and early-stage investigators (ESIs), and create opportunities for ongoing mentorship and professional development. In this manuscript, we discuss the organization of this workshop, learning objectives, supporting activities, and follow-up methods to facilitate a successful and engaging training experience. The workshop was developed through collaborative efforts with experts in CEnR, Community-Based Participatory Research (CBPR), cancer disparities, and SDOH. The workshop focused on (1) an introduction to CEnR and the opportunity for attendees to develop their own CEnR research ideas; (2) varied presentations, interactive activities, experiential learning, and discussion topics to fulfill the workshop’s learning objectives; (3) year-long opportunities for professional development and continued mentorship; and (4) evaluations of the workshop. Twenty-four ESIs and 11 clinician-scientists participated in the workshop. Using survey methods and descriptive statistics, the workshop was evaluated positively by participants. This manuscript provides guidance for both in-person and virtual workshop formats, from inception to implementation, and recommendations for other workshop facilitators. The impact of these workshops has the potential to have positive downstream implications for community-engaged research.
- Open Access
- 17 April 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (4) , e71782
Behind the Numbers: Cancer Survivor Recruitment by Demographics and Clinical Status
Background: Recruiting cancer survivors to research studies requires multiple steps that may be differentially challenging across groups of survivors. Aims: We examined associations between progression through recruitment steps and sociodemographic and clinical characteristics of survivors invited to participate in the Adapting MultiPLe behavior Interventions that eFfectively Improve (AMPLIFI) Cancer Survivor Health randomized control trial of web‐based healthy lifestyle interventions. Materials and Methods: Survivors from two population‐based cancer registries and a hospital registry ( n = 23,270) were mailed an AMPLIFI invitation letter then called by recruiters. Outcomes included being (1) reached by recruiters, (2) screened for eligibility, (3) deemed eligible, and (4) consented. Bivariate and logistic regression analyses examined associations with sociodemographic and clinical factors. Results: 7742 (33.3%) survivors were reached. Being reached was positively associated with being female, age 65+, African American, urban resident, and < 2 years from cancer diagnosis; negatively associated with colorectal cancer. Among those reached, 7438 were offered screening and 2278 (30.6%) were screened. Being screened was positively associated with being female, African American, and < 2 years from diagnosis; negatively associated with age 65+, resident in high disadvantage areas, survivor of colorectal cancer. Of survivors screened, 716 (32%) were eligible. Being eligible was positively associated with < 2 years from diagnosis; negatively associated with colorectal and kidney cancer. Of those eligible, 438(61.2%) consented to participate. Being consented was negatively associated with being African American and from high disadvantage areas. Discussion and Conclusion: Outcomes across recruitment steps vary by survivors' characteristics indicating that opportunities exist for tailored approaches to promote greater overall diversity in clinical trials.
- 17 April 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (4) , e71782
Open AccessBehind the Numbers: Cancer Survivor Recruitment by Demographics and Clinical Status
Background: Recruiting cancer survivors to research studies requires multiple steps that may be differentially challenging across groups of survivors. Aims: We examined associations between progression through recruitment steps and sociodemographic and clinical characteristics of survivors invited to participate in the Adapting MultiPLe behavior Interventions that eFfectively Improve (AMPLIFI) Cancer Survivor Health randomized control trial of web‐based healthy lifestyle interventions. Materials and Methods: Survivors from two population‐based cancer registries and a hospital registry ( n = 23,270) were mailed an AMPLIFI invitation letter then called by recruiters. Outcomes included being (1) reached by recruiters, (2) screened for eligibility, (3) deemed eligible, and (4) consented. Bivariate and logistic regression analyses examined associations with sociodemographic and clinical factors. Results: 7742 (33.3%) survivors were reached. Being reached was positively associated with being female, age 65+, African American, urban resident, and < 2 years from cancer diagnosis; negatively associated with colorectal cancer. Among those reached, 7438 were offered screening and 2278 (30.6%) were screened. Being screened was positively associated with being female, African American, and < 2 years from diagnosis; negatively associated with age 65+, resident in high disadvantage areas, survivor of colorectal cancer. Of survivors screened, 716 (32%) were eligible. Being eligible was positively associated with < 2 years from diagnosis; negatively associated with colorectal and kidney cancer. Of those eligible, 438(61.2%) consented to participate. Being consented was negatively associated with being African American and from high disadvantage areas. Discussion and Conclusion: Outcomes across recruitment steps vary by survivors' characteristics indicating that opportunities exist for tailored approaches to promote greater overall diversity in clinical trials.
- 1 January 2026
- Published by Human Kinetics in Journal of Physical Activity and Health
- Vol. 23 (9) , 1-9
Understanding the Effects of Cancer-Related Factors on the Association Between Physical Activity and Quality of Life in Breast Cancer Survivors
Background : Breast cancer survivors often experience physical and mental side effects posttreatment, compromising their quality of life (QoL). The increasing number of survivors coping with long-term side effects creates public health concerns, emphasizing the need for supportive interventions. Although physical activity (PA) benefits cancer survivors, few studies examine the effect that cancer-related factors have on the relationship between PA levels and QoL among breast cancer survivors. Understanding the associations that cancer-related factors may have on the QoL response to PA is crucial for developing effective interventions. Methods : Baseline data from 341 postprimary treatment breast cancer survivors enrolled in a web-based diet and/or exercise intervention randomized controlled trial were analyzed. PA measures included accelerometry and self-reported moderate to vigorous PA (MVPA). QoL was assessed using Patient-Reported Outcomes Measurement Information System (PROMIS) global QoL and EuroQOL-5D-5L questionnaires. Pearson correlation coefficient tests and multiple linear regression assessed associations between MVPA and QoL and whether cancer-related factors moderated these associations. Results : The EuroQOL-5D-5L QoL index (and 4 out of 5 domains) showed statistically significant associations with self-reported MVPA. PROMIS physical health was correlated with both MVPA measures. Survivors > 24 months postdiagnosis had stronger associations between accelerometry-measured MVPA levels and EuroQOL-5D-5 L QoL index ( β = 0.0004, P = .003). Survivors receiving hormone therapy exhibited stronger associations between self-reported MVPA levels and PROMIS-physical health QoL domain compared with those not ( β = 0.0121, P = .028). Conclusion : Greater MVPA was modestly associated with better QoL, with stronger associations observed in survivors receiving hormone therapy or >24 months postdiagnosis. There are potential QoL benefits in implementing interventions immediately postdiagnosis and tailoring to treatment histories.
- 1 January 2026
- Published by Human Kinetics in Journal of Physical Activity and Health
- Vol. 23 (9) , 1-9
Understanding the Effects of Cancer-Related Factors on the Association Between Physical Activity and Quality of Life in Breast Cancer Survivors
Background : Breast cancer survivors often experience physical and mental side effects posttreatment, compromising their quality of life (QoL). The increasing number of survivors coping with long-term side effects creates public health concerns, emphasizing the need for supportive interventions. Although physical activity (PA) benefits cancer survivors, few studies examine the effect that cancer-related factors have on the relationship between PA levels and QoL among breast cancer survivors. Understanding the associations that cancer-related factors may have on the QoL response to PA is crucial for developing effective interventions. Methods : Baseline data from 341 postprimary treatment breast cancer survivors enrolled in a web-based diet and/or exercise intervention randomized controlled trial were analyzed. PA measures included accelerometry and self-reported moderate to vigorous PA (MVPA). QoL was assessed using Patient-Reported Outcomes Measurement Information System (PROMIS) global QoL and EuroQOL-5D-5L questionnaires. Pearson correlation coefficient tests and multiple linear regression assessed associations between MVPA and QoL and whether cancer-related factors moderated these associations. Results : The EuroQOL-5D-5L QoL index (and 4 out of 5 domains) showed statistically significant associations with self-reported MVPA. PROMIS physical health was correlated with both MVPA measures. Survivors > 24 months postdiagnosis had stronger associations between accelerometry-measured MVPA levels and EuroQOL-5D-5 L QoL index ( β = 0.0004, P = .003). Survivors receiving hormone therapy exhibited stronger associations between self-reported MVPA levels and PROMIS-physical health QoL domain compared with those not ( β = 0.0121, P = .028). Conclusion : Greater MVPA was modestly associated with better QoL, with stronger associations observed in survivors receiving hormone therapy or >24 months postdiagnosis. There are potential QoL benefits in implementing interventions immediately postdiagnosis and tailoring to treatment histories.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor–Positive Breast Cancer
Supplementary Table 2: List of HCPCS Codes to Identify Chemotherapy
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor–Positive Breast Cancer
Supplementary Table 2: List of HCPCS Codes to Identify Chemotherapy
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor–Positive Breast Cancer
Supplementary Table 4: Kitagawa-Blinder-Oaxaca Decomposition of Race Differences in one-SD Increases of Composite Scores among Patients with Surgery Date Identified
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor–Positive Breast Cancer
Supplementary Table 4: Kitagawa-Blinder-Oaxaca Decomposition of Race Differences in one-SD Increases of Composite Scores among Patients with Surgery Date Identified
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor–Positive Breast Cancer
Supplementary Figure 1: Sample selection flow chart. * Note: This figure shows how the study inclusion and exclusion criteria were applied to derive the final primary study cohort, and the additional criteria used for the subgroup cohorts included in sensitivity analyses. Each box represents one inclusion or exclusion criterion with the corresponding sample size. Abbreviations: PCM = Patient Care Monitor, FFS = Fee-For-Service
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor–Positive Breast Cancer
Supplementary Figure 1: Sample selection flow chart. * Note: This figure shows how the study inclusion and exclusion criteria were applied to derive the final primary study cohort, and the additional criteria used for the subgroup cohorts included in sensitivity analyses. Each box represents one inclusion or exclusion criterion with the corresponding sample size. Abbreviations: PCM = Patient Care Monitor, FFS = Fee-For-Service
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor–Positive Breast Cancer
Supplementary Table 3: Kitagawa-Blinder-Oaxaca Decomposition of Race Differences in one-SD Increases of Composite Scores among Medicare Beneficiaries Subsample
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor–Positive Breast Cancer
Supplementary Table 3: Kitagawa-Blinder-Oaxaca Decomposition of Race Differences in one-SD Increases of Composite Scores among Medicare Beneficiaries Subsample
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor–Positive Breast Cancer
Supplementary Table 1: List of Individual Symptoms Used Included in Composite Scores
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor–Positive Breast Cancer
Supplementary Table 1: List of Individual Symptoms Used Included in Composite Scores
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor–Positive Breast Cancer
Supplementary Table 5: Kitagawa-Blinder-Oaxaca Decomposition of Race Differences in one-SD Increases of Composite Scores among Patients Receiving At Least 4 Cycles of Chemotherapy
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor–Positive Breast Cancer
Supplementary Table 5: Kitagawa-Blinder-Oaxaca Decomposition of Race Differences in one-SD Increases of Composite Scores among Patients Receiving At Least 4 Cycles of Chemotherapy
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor–Positive Breast Cancer
Background:Symptom burden differences may contribute to racial disparities in breast cancer survival. We compared symptom changes from before to during chemotherapy among women with breast cancer.Methods:This observational study followed a cohort of Black and White women diagnosed with Stage I–III, hormone receptor–positive breast cancer from a large cancer center in 2007 to 2015, and reported symptoms before and during chemotherapy. We identified patients who experienced a one-standard deviation (SD) increase in symptom burden after starting chemotherapy using four validated composite scores (General Physical Symptoms, Treatment Side Effects, Acute Distress, and Despair). Kitagawa–Blinder–Oaxaca decomposition was used to quantify race differences in symptom changes explained by baseline characteristics (sociodemographic, baseline scores, cancer stage) and first-line chemotherapy regimens.Results:Among 1,273 patients, Black women (n = 405, 31.8%) were more likely to report one-SD increase in General Physical Symptoms (55.6% vs. 48.2%, P = 0.015), Treatment Side Effects (74.0% vs. 63.4%, P < 0.001), and Acute Distress (27.4% vs. 20.0%, P = 0.010) than White women. Baseline characteristics and first-line chemotherapy regimens explained a large and significant proportion of the difference in Acute Distress changes (93.7%, P = 0.001), but not General Physical Symptoms (25.7%, P = 0.25) or Treatment Side Effects (16.4%, P = 0.28).Conclusions:Black women with early-stage breast cancer were more likely to experience significant increases in physical and psychological symptom burden during chemotherapy. Most of the difference in physical symptom changes remained unexplained by baseline characteristics, which suggests inadequate symptom management among Black women.Impact:Future studies should identify strategies to improve symptom management among Black women and reduce differences in symptom burden.See related commentary by Rosenzweig and Mazanec, p. 157
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor–Positive Breast Cancer
Background:Symptom burden differences may contribute to racial disparities in breast cancer survival. We compared symptom changes from before to during chemotherapy among women with breast cancer.Methods:This observational study followed a cohort of Black and White women diagnosed with Stage I–III, hormone receptor–positive breast cancer from a large cancer center in 2007 to 2015, and reported symptoms before and during chemotherapy. We identified patients who experienced a one-standard deviation (SD) increase in symptom burden after starting chemotherapy using four validated composite scores (General Physical Symptoms, Treatment Side Effects, Acute Distress, and Despair). Kitagawa–Blinder–Oaxaca decomposition was used to quantify race differences in symptom changes explained by baseline characteristics (sociodemographic, baseline scores, cancer stage) and first-line chemotherapy regimens.Results:Among 1,273 patients, Black women (n = 405, 31.8%) were more likely to report one-SD increase in General Physical Symptoms (55.6% vs. 48.2%, P = 0.015), Treatment Side Effects (74.0% vs. 63.4%, P < 0.001), and Acute Distress (27.4% vs. 20.0%, P = 0.010) than White women. Baseline characteristics and first-line chemotherapy regimens explained a large and significant proportion of the difference in Acute Distress changes (93.7%, P = 0.001), but not General Physical Symptoms (25.7%, P = 0.25) or Treatment Side Effects (16.4%, P = 0.28).Conclusions:Black women with early-stage breast cancer were more likely to experience significant increases in physical and psychological symptom burden during chemotherapy. Most of the difference in physical symptom changes remained unexplained by baseline characteristics, which suggests inadequate symptom management among Black women.Impact:Future studies should identify strategies to improve symptom management among Black women and reduce differences in symptom burden.See related commentary by Rosenzweig and Mazanec, p. 157